Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Smith & Nephew Snats ( (SNN) ) is now available.
Smith+Nephew said on April 22, 2026, that it will publish its trading report for the first quarter ended 28 March 2026 on 6 May 2026 at 7:00 a.m. BST, followed by an analyst conference call at 8:30 a.m. BST. The scheduled update underscores the company’s regular financial disclosure cycle and will provide investors and analysts with early insight into current-year trading performance and operating trends across its global medical technology portfolio.
The most recent analyst rating on (SNN) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue through its Orthopaedics, Sports Medicine & ENT and Advanced Wound Management units. Founded in Hull in 1856 and now operating in more than 100 countries, it generated $6.2 billion in sales in 2025 and is a FTSE 100 constituent listed in London and New York.
Average Trading Volume: 852,577
Technical Sentiment Signal: Buy
Current Market Cap: $14.55B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.